Why Exelixis ( EXEL ) International Revenue Trends Deserve Your Attention
Evaluate Exelixis' (EXEL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Here's Why Exelixis ( EXEL ) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Exelixis ( EXEL ) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Company News for Nov 6, 2025
Companies In The News Are: AMGN, EXEL, LITE, MCD.
EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales
Exelixis posts strong Q3 results with earnings and revenue beats, boosted by Cabometyx sales, and narrows 2025 guidance.
Exelixis ( EXEL ) Beats Q3 Earnings and Revenue Estimates
Exelixis (EXEL) delivered earnings and revenue surprises of +14.71% and +1.49%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
What's Driving the Market Sentiment Around Exelixis Inc? - Exelixis ( NASDAQ:EXEL )
Exelixis Inc's ( NYSE:EXEL ) short interest as a percent of float has risen 17.71% since its last report. According to exchange reported data, there are now 20.88 million shares sold short, which is 10.7% of all regular shares that are available for trading.
Adaptive Biotechnologies ( ADPT ) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Adaptive Biotechnologies (ADPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer - Merck & Co ( NYSE:MRK )
On Tuesday, Merck & Co. Inc. ( NYSE:MRK ) and Eisai shared topline data from the Phase 3 LITESPARK-011 trial of the dual oral regimen of Welireg ( belzutifan ) plus Lenvima ( lenvatinib ) .
Exelixis ( EXEL ) Reports Next Week: Wall Street Expects Earnings Growth
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Exelixis ( EXEL ) is Poised to Beat Earnings Estimates Again
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why Exelixis ( EXEL ) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
This Nextracker Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Exelixis ( NASDAQ:EXEL ) , Claritev ( NYSE:CTEV )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Top 3 Health Care Stocks You'll Regret Missing In October - Bayer ( OTC:BAYRY ) , Exelixis ( NASDAQ:EXEL )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
Why Is Cancer Focused Exelixis Stock Falling On Monday? - Exelixis ( NASDAQ:EXEL )
Exelixis Inc. ( NASDAQ:EXEL ) stock is trading lower on Monday after the company shared detailed results from the STELLAR-303 Phase 3 trial.
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Addex Therapeutics ( NASDAQ:ADXN ) , Alumis ( NASDAQ:ALMS )
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Monday. Shares of Olema Pharmaceuticals Inc ( NASDAQ:OLMA ) fell 18.3% to $7.64 in pre-market trading after the company announced new data from the Phase 1b/2 trial of palazestrant plus ribociclib in ...
Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket - Beyond Meat ( NASDAQ:BYND ) , Addex Therapeutics ( NASDAQ:ADXN )
Shares of Delcath Systems Inc ( NASDAQ:DCTH ) rose sharply in pre-market trading after the company announced preliminary third quarter 2025 financial results. The company's Phase 2 CHOPIN study achieved primary endpoint, with PHP plus immunotherapy extending median PFS to 12.8 months versus ...
The Ultimate Biotech Stock to Buy With $50 Right Now
This innovative drugmaker still has plenty of upside potential.
Why Exelixis ( EXEL ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Exelixis ( EXEL ) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Unlocking Cures: How AI is Reshaping Cancer Research & Healthcare ETFs?
AI's growing role in cancer research, and a new federal push for pediatric oncology, are powering gains in key healthcare ETFs.
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years
Both should have significant catalysts by the end of the decade.
LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani
NEW YORK, Sept. 25, 2025 ( GLOBE NEWSWIRE ) -- LB Pharmaceuticals Inc ( "LB Pharmaceuticals" or the "Company" ) ( Nasdaq: LBRX ) today announced the appointments of William Kane and Rekha Hemrajani to its Board of Directors effective as of the pricing of its initial public offering on September ...
LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani - LB Pharmaceuticals ( NASDAQ:LBRX )
NEW YORK, Sept. 25, 2025 ( GLOBE NEWSWIRE ) -- LB Pharmaceuticals Inc ( "LB Pharmaceuticals" or the "Company" ) ( NASDAQ: LBRX ) today announced the appointments of William Kane and Rekha Hemrajani to its Board of Directors effective as of the pricing of its initial public offering on September ...
Peering Into Exelixis's Recent Short Interest - Exelixis ( NASDAQ:EXEL )
Exelixis's EXEL short interest as a percent of float has risen 4.39% since its last report. According to exchange reported data, there are now 17.63 million shares sold short, which is 9.03% of all regular shares that are available for trading.
Here's Why Exelixis ( EXEL ) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL - Exelixis ( NASDAQ:EXEL )
NEW YORK, Sept. 06, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ( "Exelixis" or the "Company" ) EXEL. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Do Options Traders Know Something About Exelixis Stock We Don't?
Investors need to pay close attention to EXEL stock based on the movements in the options market lately.
Why Is Alkermes ( ALKS ) Up 4.7% Since Last Earnings Report?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Exelixis ( EXEL ) Up 3.8% Since Last Earnings Report?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary
Seasoned life sciences legal executive brings extensive public company experience, including broad strategic and financial transaction expertise Seasoned life sciences legal executive brings extensive public company experience, including broad strategic and financial transaction expertise ...
Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?
The FDA approval to expand Exelixis' Cabometyx into neuroendocrine tumors is witnessing encouraging uptake and boosting investor focus.
Will EXEL's Share Repurchase Program Boost Value for Investors?
Exelixis repurchases shares for $796M, aiming to boost EPS and shareholder value through 2025.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL - Exelixis ( NASDAQ:EXEL )
NEW YORK, Aug. 17, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ( "Exelixis" or the "Company" ) EXEL. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Exelixis Gains 15.6% YTD: How Should You Play the Stock?
EXEL rides on Cabometyx growth and zanzalintinib's trial success, but Q2 revenue miss and competition keep investor sentiment cautious.
Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth?
Exelixis reports strong phase III results for zanzalintinib in metastatic colorectal cancer, raising hopes beyond Cabometyx.
Is First Trust Health Care AlphaDEX ETF ( FXH ) a Strong ETF Right Now?
Smart Beta ETF report for ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exelixis, Inc. - EXEL - Exelixis ( NASDAQ:EXEL )
NEW YORK, Aug. 09, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ( "Exelixis" or the "Company" ) EXEL. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?
EXEL rides on strong Cabometyx demand in RCC and NET, but Q2 sales miss and rising competition cloud the outlook.
Exelixis EXEL Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Monday, July 28, 2025 at 9:00 p.m. ETPresident & CEO - Michael M. MorrisseyContinue reading ...
Don't Overlook Exelixis ( EXEL ) International Revenue Trends While Assessing the Stock
Explore how Exelixis' (EXEL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week ( July 28-August 1 ) : Are The Others In Your Portfolio? - ATI ( NYSE:ATI ) , Baxter Intl ( NYSE:BAX )
Novo Nordisk plunged 31% after slashing its 2025 sales outlook. UPS, Moderna, and Coinbase dropped on weak Q2 results and guidance. The next correction is closer than you think. Find out how Tom Gentile plans to trade it, live on Wednesday. These ten large-cap stocks were the worst performers ...
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View
BMY's Q2 EPS and revenues beat estimates, powered by strong Growth portfolio sales and a lesser than expected decline in Legacy portfolio sales.
Is Exelixis ( EXEL ) a Solid Growth Stock? 3 Reasons to Think "Yes"
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
2 Highly Ranked Stocks to Consider After Q2 Earnings: CLS, EXEL
Investors looking for a momentum stock that could be in store for higher highs may want to consider Celestica (CLS), while those looking for a buy-the-dip target have an intriguing option with Exelixis (EXEL).
Exelixis Stuns Analyst With Q2 Miss, Trial Delays, Phase 3 Halt - Exelixis ( NASDAQ:EXEL )
Q2 sales reaches $568.3 million, missing estimates by about $3 million; EPS beat consensus at 75 cents vs. 56 cents. Exelixis halts STELLAR-305 phase 3 plans and delays STELLAR-304 readout to first half of 2026. Missed the rally? Learn exactly where the next leaders are emerging here. Exelixis ...
All You Need to Know About Exelixis ( EXEL ) Rating Upgrade to Strong Buy
Exelixis (EXEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues
EXEL beats on Q2 earnings but misses revenues as lower collaboration income offsets strong Cabometyx sales growth.
